SMS Pharmaceuticals Posts Strong Q2FY27 Results and Raises FY27 Guidance
SMS Pharmaceuticals Ltd · Investor Presentation · 04 Nov 2026, 11:57 pm
SMS Pharmaceuticals Posts Strong Q2FY27 Results and Raises FY27 Guidance SMS Pharmaceuticals reported a 30% YoY rise in Q2FY27 revenue to ₹316.08 crore, driven by volume growth and improved realizations. EBITDA expanded 40% YoY to ₹67.65 crore with margins expanding 145 bps to 21%, while reported PAT surged 57% YoY to ₹39.57 crore. Management raised FY27 revenue growth and EBITDA margin guidance above earlier targets. Its ₹280 crore capex program remains on track for FY27 completion, targeting 1.75x net asset turnover over 2-3 years alongside scaling its peptides R&D facility.
Original exchange filing (PDF)
More announcements from SMS Pharmaceuticals Ltd
- Earnings Call Transcript · 10 Nov 2026
- Investors Meet Audio Recording · 05 Nov 2026
- Press release on Financial Results · 05 Nov 2026
- Financial results and change in Company Secretary · 04 Nov 2026
- SMS Pharmaceuticals Limited has informed the Exchange about General Updates · 04 Nov 2026
- Change in Management_Company Secretary · 04 Nov 2026
- SMS Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer · 04 Nov 2026
- Outcome of Board Meeting and Financial Results · 04 Nov 2026
